Back

Ultragenyx shares plunge 44.03% after Phase 3 trial misses endpoints

Verifying
  • Pomerantz LLP is investigating Ultragenyx over possible securities law violations.
  • 44.03%: Ultragenyx shares fell $11.68 to close at $14.85.
  • Ultragenyx announced the Aspire study results on September 2, 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.